After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.
…
Sanofi-Aventis CEO Chris Viehbacher said Wednesday that he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme at a reasonable price. However, he expects it will take some time to agree o…
Genzyme (GENZ) announced that it has agreed to sell Genzyme Genetics to Laboratory Corporation of America Holdings (LabCorp) (LH) for for $925 million in cash.
Cambridge, Mass.-based Genzyme said that under the terms of the agreement, LabCorp will pur…
Genzyme (GENZ) announced that it has agreed to sell Genzyme Genetics to Laboratory Corporation of America Holdings (LabCorp) (LH) for for $925 million in cash.
Cambridge, Mass.-based Genzyme said that under the terms of the agreement, LabCorp will pur…